Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Negative feedback Inhibition of NFATc1 by DYRK1A regulates bone homeostasis.

Lee Y, Ha J, Kim HJ, Kim YS, Chang EJ, Song WJ, Kim HH.

J Biol Chem. 2009 Nov 27;284(48):33343-51. doi: 10.1074/jbc.M109.042234. Epub 2009 Oct 2.

2.

The small molecule harmine regulates NFATc1 and Id2 expression in osteoclast progenitor cells.

Egusa H, Doi M, Saeki M, Fukuyasu S, Akashi Y, Yokota Y, Yatani H, Kamisaki Y.

Bone. 2011 Aug;49(2):264-74. doi: 10.1016/j.bone.2011.04.003. Epub 2011 Apr 12.

PMID:
21504804
4.

BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.

Valverde P, Tu Q, Chen J.

J Bone Miner Res. 2005 Sep;20(9):1669-79. Epub 2005 May 16.

5.

Calcineurin/NFAT signaling in osteoblasts regulates bone mass.

Winslow MM, Pan M, Starbuck M, Gallo EM, Deng L, Karsenty G, Crabtree GR.

Dev Cell. 2006 Jun;10(6):771-82.

7.

TRAF2 is essential for TNF-alpha-induced osteoclastogenesis.

Kanazawa K, Kudo A.

J Bone Miner Res. 2005 May;20(5):840-7. Epub 2004 Dec 20.

8.

Inhibitory effects of Stewartia koreana on osteoclast differentiation and bone resorption.

Park CK, Kim HJ, Kwak HB, Lee TH, Bang MH, Kim CM, Lee Y, Chung DK, Baek NI, Kim J, Lee ZH, Kim HH.

Int Immunopharmacol. 2007 Dec 5;7(12):1507-16. Epub 2007 Aug 8.

PMID:
17920527
9.

RGS18 acts as a negative regulator of osteoclastogenesis by modulating the acid-sensing OGR1/NFAT signaling pathway.

Iwai K, Koike M, Ohshima S, Miyatake K, Uchiyama Y, Saeki Y, Ishii M.

J Bone Miner Res. 2007 Oct;22(10):1612-20.

10.

Diphenylhydantoin inhibits osteoclast differentiation and function through suppression of NFATc1 signaling.

Koide M, Kinugawa S, Ninomiya T, Mizoguchi T, Yamashita T, Maeda K, Yasuda H, Kobayashi Y, Nakamura H, Takahashi N, Udagawa N.

J Bone Miner Res. 2009 Aug;24(8):1469-80. doi: 10.1359/jbmr.090302.

11.

Harmine, a β-carboline alkaloid, inhibits osteoclast differentiation and bone resorption in vitro and in vivo.

Yonezawa T, Hasegawa S, Asai M, Ninomiya T, Sasaki T, Cha BY, Teruya T, Ozawa H, Yagasaki K, Nagai K, Woo JT.

Eur J Pharmacol. 2011 Jan 15;650(2-3):511-8. doi: 10.1016/j.ejphar.2010.10.048. Epub 2010 Nov 1.

PMID:
21047508
12.

DDR2 (discoidin domain receptor 2) suppresses osteoclastogenesis and is a potential therapeutic target in osteoporosis.

Zhang Y, Su J, Wu S, Teng Y, Yin Z, Guo Y, Li J, Li K, Yao L, Li X.

Sci Signal. 2015 Mar 24;8(369):ra31. doi: 10.1126/scisignal.2005835.

PMID:
25805889
13.

Coptisine inhibits RANKL-induced NF-κB phosphorylation in osteoclast precursors and suppresses function through the regulation of RANKL and OPG gene expression in osteoblastic cells.

Lee JW, Iwahashi A, Hasegawa S, Yonezawa T, Jeon WB, Cha BY, Nagai K, Woo JT.

J Nat Med. 2012 Jan;66(1):8-16. doi: 10.1007/s11418-011-0537-7. Epub 2011 Jun 9.

PMID:
21656335
14.

The R740S mutation in the V-ATPase a3 subunit increases lysosomal pH, impairs NFATc1 translocation, and decreases in vitro osteoclastogenesis.

Voronov I, Ochotny N, Jaumouillé V, Owen C, Manolson MF, Aubin JE.

J Bone Miner Res. 2013 Jan;28(1):108-18. doi: 10.1002/jbmr.1727.

15.

Atm-deficient mice: an osteoporosis model with defective osteoblast differentiation and increased osteoclastogenesis.

Rasheed N, Wang X, Niu QT, Yeh J, Li B.

Hum Mol Genet. 2006 Jun 15;15(12):1938-48. Epub 2006 Apr 27.

PMID:
16644862
16.

Overexpression of DYRK1A inhibits choline acetyltransferase induction by oleic acid in cellular models of Down syndrome.

Hijazi M, Fillat C, Medina JM, Velasco A.

Exp Neurol. 2013 Jan;239:229-34. doi: 10.1016/j.expneurol.2012.10.016. Epub 2012 Nov 1.

PMID:
23124096
17.

Tanshinone IIA inhibits osteoclast differentiation through down-regulation of c-Fos and NFATc1.

Kwak HB, Yang D, Ha H, Lee JH, Kim HN, Woo ER, Lee S, Kim HH, Lee ZH.

Exp Mol Med. 2006 Jun 30;38(3):256-64.

18.

Enhanced expression of DYRK1A in cardiomyocytes inhibits acute NFAT activation but does not prevent hypertrophy in vivo.

Grebe C, Klingebiel TM, Grau SP, Toischer K, Didié M, Jacobshagen C, Dullin C, Hasenfuss G, Seidler T.

Cardiovasc Res. 2011 Jun 1;90(3):521-8. doi: 10.1093/cvr/cvr023. Epub 2011 Jan 27.

PMID:
21273244
19.

Regulators of G protein signaling 12 promotes osteoclastogenesis in bone remodeling and pathological bone loss.

Yuan X, Cao J, Liu T, Li YP, Scannapieco F, He X, Oursler MJ, Zhang X, Vacher J, Li C, Olson D, Yang S.

Cell Death Differ. 2015 Dec;22(12):2046-57. doi: 10.1038/cdd.2015.45. Epub 2015 Apr 24.

20.

Nuclear factor of activated T cells c1 induces osteoclast-associated receptor gene expression during tumor necrosis factor-related activation-induced cytokine-mediated osteoclastogenesis.

Kim K, Kim JH, Lee J, Jin HM, Lee SH, Fisher DE, Kook H, Kim KK, Choi Y, Kim N.

J Biol Chem. 2005 Oct 21;280(42):35209-16. Epub 2005 Aug 18.

Supplemental Content

Support Center